Potential cell therapy for Epidermolysis Bullosa (EB)
Source: IMAPAC
In partnership with Mesoblast Limited, JCR Pharmaceuticals has filed to extend the marketing approval of TEMCELL, a mesenchymal stem cell (MSC) wound healing product for patients with Epidermolysis Bullosa (EB).
JCR has received an orphan drug designation for subcutaneous treatment of TEMCELL for EB, and are currently seeking a label extension for intravenous delivery of TEMCELL in Japan. There is no cure for EB in the current market, but MSC therapy using TEMCELL has shown promising signs in an investigator-initiated trial.
TEMCELL was the first allogeneic cellular medicine to receive the full regulatory approval in Japan, previously indicated for treatment of acute graft versus host disease (aGVHD). JCR’s clinical trial data on TEMCELL for EB in Japan will also aid Mesoblast’s development and commercialization of their MSC treatment for aGVHD.
With the good news from JCR’s clinical data on TEMCELL in Japan, there is hope of creating the first ever effective treatment for EB, a rare genetic skin disorder that causes fragile skin that blisters from gentle friction or rubbing. (Source)
-
Most popular related searches
Customer comments
No comments were found for Potential cell therapy for Epidermolysis Bullosa (EB). Be the first to comment!